drugset / Trial / NCT06839105
A Clinical Study to Evaluate the Safety and Tolerability of AWT020 in Patients With Advanced Malignancies
Non-randomizedSequentialOpen-labelTreatment
Summary
The purpose of this phase I clinical study was to evaluate the safety and tolerability of AWT020 monotherapy and combination with other antitumor therapies in patients with advanced malignancies
Timeline
- Start
- 2025-02-21
- Primary completion
- 2028-04-30
- Completion
- 2028-04-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | AWT020 | Unknown | — | Intravenous |
| Background | Bevacizumab | Monoclonal antibody | 7.5 mg/kg | — |
| Background | Capecitabine | Small molecule | 1000 mg/m2 | Oral |
| Background | Carboplatin | Small molecule | 5 unknown | — |
| Background | Carboplatin | Small molecule | 6 unknown | — |
| Background | Cisplatin | Other / unclassified | 75 mg/m2 | — |
| Background | Oxaliplatin | Small molecule | 130 mg/m2 | — |
| Background | Paclitaxel | Small molecule | 135 mg/m2 | — |
| Background | Paclitaxel | Small molecule | 175 mg/m2 | — |
| Background | Pemetrexed | Small molecule | 500 mg/m2 | — |
| Background | Renvastinib | Unknown | 8 mg | — |
| Background | Renvastinib | Unknown | 20 mg | — |